You are here

PORTABLE GENE SCANNER

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: GM57108-01
Agency Tracking Number: 39409
Amount: $99,997.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 1997
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
AND INSTRUMENT, INC.
Woburn, MA 01801
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 HANG, JIM
 () -
Business Contact
Phone: (617) 273-8854
Research Institution
N/A
Abstract

DESCRIPTION: The investigator proposes to design a small confocal planar array that will be capable of point-by-point scanning of a chip carrying fluorescent probes hybridized to a Si-based substrate. The entire chip would be designed to fit in the CD port of a laptop computer which could be used in clinical labs, offices, and in the field. If successful, the unit would cost about $5,000. For comparison, the Affymetrix scanner will soon be marketed for $80,000. $ = TOTAL AWARD AMTS & NOT LIMITED TO PORTION OF PROJECT RELATED TO SUBJECT OF SEARCH SUBPROJECT $ = TOTAL AWARD AMOUNT DIVIDED BY NUMBER OF SUBPROJECTS SOURCE: CRISP FORMAT F FY 97 LAST UPDATE 04-07-98 1QUERY 1536 ID SEARCH 06/01/98 PAGE 355 --PROJECT NUMBER......1 R43 GM57109-01 INVESTIGATOR NAME/ADDRESS FY 97 PACHENCE, JAMES M IRG/INTRAMURAL UNIT..ZRG7 VERITAS MEDICAL TECH, INC AWARD AMOUNT......... $100,000 116 VILLAGE BLVD, SUITE 200 PRINCETON, NJ 08540-5799 PERFORMING ORGANIZATION: VERTIAS MEDICAL TECHNOLOGIES, INC. TITLE PREVENTING OF POSTSURGICAL ADHESIONS ABSTRACT: DESCRIPTION (Adapted from applicant's abstract): Surgical intervention, by its very nature, results in tissue damage that triggers the formation of fibrotic scar tissue as part of the normal wound healing response. Although inflammation and production of extracellular matrix components is necessary for normal wound healing, adhesions may also occur which can lead to significant clinical complications. Simple bioresorbable barriers made from hyaluronic acid, regenerated cellulose, or collagen have been shown to have some efficacy in preventing inter-tissue adhesions, but there are still a significant number of adhesions that occur using this strategy. Another strategy to eliminate post-surgical adhesions is to provide an absorbable barrier between tissue planes which releases an agent which inhibits collagen production, the main protein component of scar tissue. For example, cis-4-hydroxyproline (cHyp) has been shown to be a potent inhibitor of synthesis of collagen, and thus has been considered as a potential antifibrotic agent. However, free cHyp is too toxic to be used as a clinical agent, primarily due to its effects on non-collagen proteins. To reduce the toxicity of this agent, cHyp was attached to a water soluble polymer consisting of low molecular weight polyethylene glycol (PEG) and the amino acid lysine (Lys). The lysine component has a free carboxylic acid pendent group at each monomeric repeat unit which can be used to couple active agents such as cHyp. A series of preliminary in vitro and in vivo studies has established the use of this polymer for the delivery of cHyp, showing that collagen production can be effectively inhibited without other cytotoxic effects. The scientific objectives of this Phase I proposal is to establish a formulation of the PEG-Lys-cHyp polymer which can be used in conjunction with a bioresorbable delivery system to combat post-surgical adhesion formation. A well-described animal model which reliably produces adhesions will be utilized to develop an effective formulation. $ = TOTAL AWARD AMTS & NOT LIMITED TO PORTION OF PROJECT RELATED TO SUBJECT OF SEARCH SUBPROJECT $ = TOTAL AWARD AMOUNT DIVIDED BY NUMBER OF SUBPROJECTS SOURCE: CRISP FORMAT F FY 97 LAST UPDATE 04-07-98 1QUERY 1536 ID SEARCH 06/01/98 PAGE 356 --PROJECT NUMBER......1 R43 GM57134-01 INVESTIGATOR NAME/ADDRESS FY 97 OLEJNIK, JERZY IRG/INTRAMURAL UNIT..ZRG3 AMBERGEN, INC AWARD AMOUNT......... $100,000 1106 COMMONWEALTH AVENUE BOSTON, MA 02215 PERFORMING ORGANIZATION: AMBERGEN, INC. TITLE PHOTOCLEAVABLE LINKERS AND MARKERS FOR MASS SPECTROMETRY ABSTRACT: DESCRIPTION: (Adapted from the applicant's abstract) The goal of this project is to develop a new technology for the detection and analysis of biomolecules based on novel photocleavable linkers (PC-linkers), photocleavable-markers (PC-markers) and matrix assisted laser desorption mass spectrometry (MALDI-MS). AmberGen, Inc. has demonstrated that biomolecules can be captured on a surface using PC-linkers and then photreleased and detected using MALDI-MS. Biomolecules can also be detected with high sensitivity by MALDI-MS using probes which contain PC- markers. PC-linkers and PC-markers are introduced into biomolecules using proprietary reagents developed by AmberGen, Inc. Examples include PC-phosphoramidites for 5'-end labeling of an oligonucleotide during solid-support synthesis and PC-NHS-esters for labeling of proteins and polypeptides. During Phase I this new technology will be evaluated by incorporating PC-linkers and PC-markers into a variety of biomolecules including nucleic acids, proteins and polypeptides and analyzing these molecules by MALDI-MS. Substrates containing uniform and microfabricated 2-D patterned arrays of biomolecules containing PC-linkers and PC-markers will be produced and evaluated using MALDI-MS. PC-linkers and PC-markers combined with MALDI-MS have numerous applications for molecular diagnosis such as DNA analysis, nascent protein analysis and drug screening. $ = TOTAL AWARD AMTS & NOT LIMITED TO PORTION OF PROJECT RELATED TO SUBJECT OF SEARCH SUBPROJECT $ = TOTAL AWARD AMOUNT DIVIDED BY NUMBER OF SUBPROJECTS SOURCE: CRISP FORMAT F FY 97 LAST UPDATE 04-07-98 1QUERY 1536 ID SEARCH 06/01/98 PAGE 357 --PROJECT NUMBER......1 R43 GM57135-01 INVESTIGATOR NAME/ADDRESS FY 97 KELLER, MARTIN IRG/INTRAMURAL UNIT..ZRG3 RECOMBINANT BIOCATALYSIS INC AWARD AMOUNT......... $99,082 10665 SORRENTO VALLEY RD SAN DIEGO, CA 92121 PERFORMING ORGANIZATION: DIVERSA CORPORATION TITLE FLUORESCENT ACTIVATED CELL SORTING FOR ENZYME SCREENING ABSTRACT: There has been increasing demand in the research reagent, diagnostic reagent and chemical process industries for protein-based catalysts possessing novel capabilities. At present, this need is largely addressed using enzymes purified from a variety of cultivated microorganisms, generally members of the domains Bacteria and Archaea. However, because less than 1% of naturally occurring microorganisms have been grown in culture, alternative techniques must be developed to exploit the full breadth of diversity for potentially valuable new products. We propose to develop fluorescent activated cell sorting for an extreme high throughput screening for recombinant expression clones from uncultivated organisms to discover a large number of unique, robust, specific biocatalysts for the cost effective synthesis of chiral synthons for use in production of pharmaceuticals, biological intermediates and natural products.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government